SRC and osteosarcoma: After verifying the inhibitory effects of daidzein on osteosarcoma in vitro and in vivo, we applied systemic pharmacology theory and molecular docking analysis to identify the intersection of potential targets between osteosarcoma and daidzein, and selected the key target, Src, and its downstream MAPK pathway.